Ultragenyx Therapeutics

Ultragenyx Therapeutics is a commercial-stage biopharmaceutical company dedicated to bringing novel therapies to patients with rare and ultra-rare genetic diseases. The company has successfully commercialized several products, including Crysvita for X-linked hypophosphatemia and Dojolvi for long-chain fatty acid oxidation disorders. Their diverse development strategy spans multiple modalities such as small molecules, monoclonal antibodies, and gene therapies. Ultragenyx maintains a robust late-stage pipeline with programs targeting conditions like Angelman syndrome, Wilson disease, and various glycogen storage diseases. By focusing on diseases with high unmet medical needs and clear biological mechanisms, the company aims to deliver transformative treatments to underserved patient populations globally. The company also leverages proprietary manufacturing platforms, such as the HeLa P4 AAV system, to support its gene therapy portfolio.